Olaparib + Sapacitabine in BRCA Mutant Breast Cancer
Olaparib + Sapacitabine in BRCA Mutant Breast Cancer
Active, not recruiting · NCT03641755 · Registry updated 2026-02-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Olaparib + Sapacitabine in BRCA Mutant Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 1 | 2026-02-23 | NCT03641755 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
| Cyclacel Pharmaceuticals, Inc. | 1 |
| Dana-Farber Cancer Institute | 324 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Broad Institute of MIT | Cambridge | United States | 1 |
| Dana Farber Cancer Institute | Boston | United States | 300 |